Jane de Lartigue, PhD | Authors

March 21, 2018

Since the identification of the role of the JAK kinase family in the late 1980s, awareness of this has grown significantly. These tyrosine kinases have been proven to transmit a variety of signals into the cells with many biological consequences, adding to the interest in the targetability of the JAK pathway. However, better understanding of the complexities of JAK signaling are being evaluated in clinical trials.

November 13, 2017

Chimeric antigen receptor T cells have hit the prime time, with 2 FDA approvals already for this class of cellbased therapy. Undoubtedly this will be a game changer for patients with B-cell malignancies who have a small number of treatment options; however, questions regarding the realworld application of CAR T-cell therapies remain.

January 28, 2015

Metastatic disease accounts for the vast majority of cancer-related deaths. Ensuring a definitive diagnosis and the most effective treatment in a timely fashion is essential for extending life expectancy.

September 20, 2014

The 5-year survival rate for patients with metastatic colorectal cancer (CRC) remains dismal. Liver metastases are a particularly common occurrence, developing in approximately half of all patients with colorectal cancer.

August 01, 2014

For nearly 2 decades, researchers have been exploring B-cell–specific antigens in hopes of developing a new anticancer target that could surpass the success of CD20-targeting agents.

July 31, 2014

Treatment for non-small cell lung cancer (NSCLC)—which includes adenocarcinoma, squamous cell carcinoma, and large cell carcinoma—has traditionally consisted of surgery, chemotherapy, and radiation therapy.